Re: nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.
Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria; Department of Urology, Rennes University Hospital, Rennes, France.
Romain
R
Mathieu
Department of Urology, Medical University Vienna, General Hospital, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at.
Shahrokh F
SF
Shariat
D000726:Androgen Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood*
D000726:Androgen Antagonists; D013739:Testosterone